← Back to Search

Glucagon-like peptide-1 receptor agonist

Semaglutide for Coronary Artery Disease (STOP Trial)

Phase 4
Waitlist Available
Led By Matthew Budoff, MD
Research Sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights

STOP Trial Summary

This trial will study whether the diabetes medication Semaglutide can help treat atherosclerosis, or hardening of the arteries.

Eligible Conditions
  • Coronary Artery Disease
  • Type 2 Diabetes

STOP Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Rate of change in non-calcified plaque volume
Secondary outcome measures
Rate of change in total plaque volume

STOP Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: SemaglutideActive Control1 Intervention
Semaglutide 2mg/1.5 ml (1.34 mg/ml) Prefilled pen for SQ injection
Group II: PlaceboPlacebo Group1 Intervention
Placebo 1.5 ml, pen-injector for SC injection.

Find a Location

Who is running the clinical trial?

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical CenterLead Sponsor
101 Previous Clinical Trials
46,161 Total Patients Enrolled
8 Trials studying Coronary Artery Disease
7,736 Patients Enrolled for Coronary Artery Disease
Matthew Budoff, MDPrincipal InvestigatorLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
7 Previous Clinical Trials
1,103 Total Patients Enrolled
2 Trials studying Coronary Artery Disease
164 Patients Enrolled for Coronary Artery Disease

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Semaglutide Treatment On Coronary Progression
Matthew J. Budoff 2019. "Semaglutide Treatment On Coronary Progression". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03985384.
~24 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top